Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
30.1M
-
Shares change
-
+1.1M
-
Total reported value, excl. options
-
$1.17B
-
Value change
-
+$49M
-
Put/Call ratio
-
0.44
-
Number of buys
-
82
-
Number of sells
-
-44
-
Price
-
$38.82
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2016
161 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2016.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.1M shares
of 108M outstanding shares and own 27.94% of the company stock.
Largest 10 shareholders include FMR LLC (6.48M shares), VANGUARD GROUP INC (2.36M shares), TimesSquare Capital Management, LLC (1.62M shares), JENNISON ASSOCIATES LLC (1.28M shares), BlackRock Advisors LLC (1.26M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.1M shares), BlackRock Fund Advisors (1.04M shares), Redmile Group, LLC (972K shares), ORBIMED ADVISORS LLC (885K shares), and WASATCH ADVISORS INC (812K shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.